PANCREASE MT 16 70000 UNIT
AMYLASE : 70000 UNIT LIPASE : 16800 UNIT PROTEASE : 40000 UNIT · DIN 00789429 · VIVUS LLC.
Health Canada status: MARKETED
What is PANCREASE MT 16?
PANCREASE MT 16 70000 UNIT contains AMYLASE : 70000 UNIT LIPASE : 16800 UNIT PROTEASE : 40000 UNIT. It is listed in the Health Canada Drug Product Database under DIN 00789429, held by VIVUS LLC., supplied as CAPSULE (DELAYED RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 09-Aug-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PANCREASE MT 16 used for?
Treatment of pancreatic insufficiency attributed to cystic fibrosis, chronic pancreatitis, or other medically defined pancreatic disease requiring enzyme therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00789429 |
|---|---|
| Brand name | PANCREASE MT 16 |
| Generic / active ingredient | AMYLASE : 70000 UNIT LIPASE : 16800 UNIT PROTEASE : 40000 UNIT |
| Manufacturer | VIVUS LLC. |
| Strength | 70000 UNIT |
| Dosage form | CAPSULE (DELAYED RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 09-Aug-2019 |
How is it administered?
Individualized based on severity of deficiency and fat intake. Infants: 2,000-4,000 units/120mL formula. Adults/Children: 500-1,000 units/kg/meal. Max 2,500 units/kg/meal or 6,000 units/kg/meal.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 10°C to 25°C in a dry place. Keep bottle tightly closed. Do not refrigerate.
How is it supplied?
Bottles of 100 capsules for each strength. Contains a desiccant canister.
Contraindications
Hypersensitivity to porcine protein, pancreatic enzymes, or excipients; acute pancreatitis or acute exacerbation of chronic pancreatitis.
Warnings and precautions
Fibrosing colonopathy (strictures) associated with high doses (>6,000 units/kg/meal). Do not substitute with other products. Ensure adequate hydration. Avoid retention in mouth to prevent ulcers.
What can be used instead?
Other Canadian products sharing ATC code A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC). 14 of 65 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| COTAZYM | 35000 UNIT | CAPSULE (IMMEDIATE RELEASE) | ORGANON CANADA INC. | MARKETED | DIN 00263818 |
| COTAZYM ECS 20 | 25000 UNIT | CAPSULE (DELAYED RELEASE) | ORGANON CANADA INC. | MARKETED | DIN 00821373 |
| COTAZYM ECS 8 | 10800 UNIT | CAPSULE (DELAYED RELEASE) | ORGANON CANADA INC. | MARKETED | DIN 00502790 |
| CREON MINIMICROSPHERES 10 | 10000 UNIT | CAPSULE (DELAYED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02200104 |
| CREON MINIMICROSPHERES 25 | 25000 UNIT | CAPSULE (DELAYED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 01985205 |
| CREON MINIMICROSPHERES 35 | 35700 UNIT | CAPSULE (DELAYED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02494639 |
| CREON MINIMICROSPHERES MICRO | 5000 UNIT / 100 MG | GRANULES FOR SUSPENSION, DELAYED RELEASE | BGP PHARMA ULC | MARKETED | DIN 02445158 |
| PANCREASE MT 10 | 43750 UNIT | CAPSULE (DELAYED RELEASE) | VIVUS LLC. | MARKETED | DIN 00789437 |
| PANCREASE MT 2 | 6200 UNIT | CAPSULE (DELAYED RELEASE) | VIVUS LLC. | MARKETED | DIN 02503433 |
| PANCREASE MT 20 | 37000 UNIT | CAPSULE (DELAYED RELEASE) | VIVUS LLC. | MARKETED | DIN 02503441 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.